TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report)’s stock price traded down 2.7% during trading on Friday . The stock traded as low as $0.41 and last traded at $0.42. 1,391,477 shares changed hands during mid-day trading, an increase of 110% from the average session volume of 662,359 shares. The stock had previously closed at $0.43.
TNF Pharmaceuticals Stock Down 2.7 %
The company’s fifty day moving average is $0.95.
TNF Pharmaceuticals Company Profile
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
Read More
- Five stocks we like better than TNF Pharmaceuticals
- Financial Services Stocks Investing
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- What is the Australian Securities Exchange (ASX)
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- What is a Secondary Public Offering? What Investors Need to Know
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
